Best-value biological medicines: Ustekinumab
The Medicines Management Programme has identified best-value biological (BVB) medicines for medicinal products containing ustekinumab.
The MMP recommends the following as BVB medicines for ustekinumab:
- Imuldosa® (Accord Healthcare Ireland Limited)
- Otulfi® (Fresenius Kabi Ireland)
- Pyzchiva® (Sandoz Limited trading as Rowex)
- Wezenla® (Amgen Ireland Limited)
Clinicians should give due consideration to prescribing Imuldosa®, Otulfi®, Pyzchiva® or Wezenla® when issuing a prescription for ustekinumab for the treatment of plaque psoriasis, psoriatic arthritis or Crohn’s disease.
A copy of the MMP Evaluation Report is available in the Related Files section below.